Associatie dermatologie Maldegem
- Address
- lock Available on a paid plan
Immune System Diseases and Chronic Skin Allergy Research
At Associatie dermatologie Maldegem, clinical trials in immune system diseases focus on chronic spontaneous urticaria and related allergic skin conditions. The research is centered on finding better ways to reduce itching, hives, and overall disease activity, while also improving long-term symptom control for patients.
- Evaluating new treatments for chronic spontaneous urticaria
- Measuring reductions in urticaria activity and symptom burden
- Supporting more durable control of allergic skin disease
These studies aim to test whether emerging therapies can offer stronger and more sustained relief than current care.
Skin and Connective Tissue Diseases in Psoriasis
The site is also active in trials for skin and connective tissue diseases, with a strong emphasis on moderate to severe plaque psoriasis and moderate-to-severe psoriasis. This work explores ways to improve treatment effectiveness, maintain disease control over time, and assess the safety of newer biologic and targeted therapies.
- Studying better disease control in plaque psoriasis
- Comparing treatment strategies for long-term psoriasis management
- Evaluating the safety and effectiveness of newer biologic therapies
These trials help clarify how to keep psoriasis symptoms under control while supporting safer, more personalized care.
Inflammatory Itch Conditions and Atopic Dermatitis
Research at this Belgian dermatology clinic includes studies in atopic dermatitis and neurodermatitis, with a particular focus on persistent itch and skin inflammation. The trials are designed to assess whether newer topical or systemic options can improve daily comfort and reduce the impact of chronic skin irritation.
- Testing treatments for moderate atopic dermatitis
- Addressing persistent pruritus in chronic itching disorders
- Exploring options for patients not well controlled with standard therapies
Overall, the research aims to improve symptom relief and quality of life for people living with long-lasting inflammatory skin disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Celldex Therapeutics Inc.1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Associatie dermatologie Maldegem
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | Amgen Inc. | Phase III | Not Recruiting | Oct 2023 | Jun 2026 |
IMP list
lock Showing 1 of 11 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Barzolvolimab | 2 | Unknown | 2024-12-16 | 2026-04-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.